Evidence map›Paper›PMID 40064839›Full record

Observational studyJournal of thrombosis and thrombolysis2025

Tissue factor pathway inhibitor levels and atherothrombotic events in patients with chronic kidney disease or diabetes.

Rowena Brook, Mani Suleiman, Joseph Rigano, Brandon Lui, Harshal Nandurkar, Prahlad Ho, Hui Yin Lim

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rowena BrookNorthern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Melbourne, Australia. Rowena.brook@nh.org.au.ORCID http://orcid.org/0000-0002-8369-1876
Mani SuleimanResearch Development and Governance Unit, Northern Health, Melbourne, VIC, Australia.
Joseph RiganoNorthern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Melbourne, Australia.
Brandon LuiNorthern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Melbourne, Australia.
Harshal NandurkarDepartment of Haematology, Northern Health, Melbourne, Australia.
Prahlad HoNorthern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Melbourne, Australia.
Hui Yin LimNorthern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased tissue factor pathway inhibitor (TFPI) has been associated with cardiovascular disease (CVD). We aim to evaluate the predictive capability of TFPI for atherothrombotic events (ATE) in patients with chronic kidney disease (CKD) and diabetes. A prospective observational study was performed at Northern Health, Australia. Patients with CKD (estimated glomerular filtration ratio (eGFR) < 30 ml/min/1.73m

Indexed as

Diabetes MellitusLipoproteinsRenal Insufficiency, ChronicThrombosisAgedFemaleHumansMaleMiddle AgedProspective StudiesRisk Factorslipoprotein-associated coagulation inhibitorLipoproteinsCardiovascular diseasesDiabetes mellitusRenal insufficiency, chronicTissue factor pathway inhibitor

Identifiers

PMID40064839
PMCPMC12009229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.